Jecture, a validated manufacturer of critical patient-interface cannula systems, has entered into a strategic collaboration with Quantum Innovation in the field of direct cardiac surgery applications. The collaboration focuses on the development and industrialization of cardiac surgery devices, where patient-proximal components require maximum reproducibility, regulatory control, and long-term lifecycle stability.
By combining Jecture’s proven expertise in precision cannula manufacturing for validated Tier-1 programs with Quantum Innovation’s application-driven development approach in cardiac surgery, the partnership is designed to reduce qualification risk and accelerate time-to-market for regulated cardiac surgery programs. Jecture contributes needle and cannula systems already validated in global Tier-1 combination-product programs, providing:
- controlled geometry, surface and silicone systems for reproducible patient experience,
- strict change-discipline with formal PCNs and OEM approvals,
- and lifecycle stability over long program durations, avoiding re-validation risks during serial supply.
All developments within this collaboration follow international regulatory requirements for cardiac surgery devices and are supported by audit-proven manufacturing processes, traceable documentation and fast CAPA cycles, ensuring predictable compliance throughout the product lifecycle.
During a technical alignment meeting at Jecture Poland, we had the pleasure of hosting representatives from Quantum Innovation like Mr Przemysław Furdal, Founder and Board Vice President and Ms Karolina Fiączyk, Director of Research & Development and Technology Transfer . The collaboration underlines Jecture’s role as a risk-reducing interface between needle manufacturing and regulated cardiac surgery programs, supporting partners from development through industrialization and long-term series supply.
